Specification
Description
BTA-9881, also known as AZD-9639 and MEDI-564, is a viral fusion protein inhibitor potentially for the treatment of respiratory syncytial virus infection.
Synonyms
BTA-9881; BTA 9881; BTA9881; AZD-9639; AZD9639;AZD 9639; MEDI-564; MEDI564; MEDI 564
IUPAC Name
(S)-9b-(4-chlorophenyl)-1-nicotinoyl-1,2,3,9b-tetrahydro-5H-imidazo[1',2':1,2]pyrrolo[3,4-c]pyridin-5-one
Canonical SMILES
O=C1N2[C@@](C3=C1C=CN=C3)(C4=CC=C(Cl)C=C4)N(C(C5=CC=CN=C5)=O)CC2
InChI
InChI=1S/C21H15ClN4O2/c22-16-5-3-15(4-6-16)21-18-13-24-9-7-17(18)20(28)26(21)11-10-25(21)19(27)14-2-1-8-23-12-14/h1-9,12-13H,10-11H2/t21-/m1/s1
InChI Key
QZSZPSDRJPPZDZ-OAQYLSRUSA-N
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Storage
Dry, dark and at 0-4 °C for short term (days to weeks) or -20 °C for long term (months to years).
Biological Target
BTA-9881, also known as AZD-9639 and MEDI-564, is a viral fusion protein inhibitor potentially for the treatment of respiratory syncytial virus infection.
Drug Formulation
This drug may be formulated in DMSO
Elemental Analysis
C, 64.54; H, 3.87; Cl, 9.07; N, 14.34; O, 8.19
HS Tariff Code
2934.99.9001
Shipping
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Stock Solution Storage
0-4 °C for short term (days to weeks), or -20 °C for long term (months).